FDA Accepts Palvella’s QTORIN NDA for Priority Review
The FDA set February 28, 2027, as the PDUFA target action date for QTORIN rapamycin.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA Accepts Palvella’s QTORIN NDA for Priority Review
The FDA accepted Palvella’s QTORIN rapamycin NDA for priority review, with a February 28, 2027 PDUFA target action date.